Platelets are a previously unrecognised source of MIF

Tim Strüßmann; Sabine Tillmann; Theresa Wirtz; Richard Bucala; Philipp von Hundelshausen; Jürgen Bernhagen

doi:10.1160/TH13-01-0049

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2013; 110(05): 1004-1013
DOI: 10.1160/TH13-01-0049

Platelets and Blood Cells

Schattauer GmbH

Platelets are a previously unrecognised source of MIF

Authors

Tim Strüßmann^*

¹Institute of Biochemistry and Molecular Cell Biology, RWTH Aachen University, Aachen, Germany
Sabine Tillmann^*

¹Institute of Biochemistry and Molecular Cell Biology, RWTH Aachen University, Aachen, Germany
Theresa Wirtz

¹Institute of Biochemistry and Molecular Cell Biology, RWTH Aachen University, Aachen, Germany
Richard Bucala

²Yale University School of Medicine, New Haven, Connecticut, USA
Philipp von Hundelshausen

³Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany
Jürgen Bernhagen

¹Institute of Biochemistry and Molecular Cell Biology, RWTH Aachen University, Aachen, Germany

⁴August-Lenz-Stiftung, Institute for Cardiovascular Research, Ludwig-Maximilians-University Munich, Munich, Germany

Abstract

Summary

Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine with chemokine-like functions and a role in atherogenesis. MIF is secreted by various cells including endothelial cells and macrophages. Platelets are another prominent cell type with a role in atherogenesis and are a rich source of atherogenic chemokines. We asked whether platelets express and secrete MIF. In comparison, CXCL12 release was determined. We examined the subcellular localisation of MIF in platelets/ megakaryocytes, studied its co-localisation with other plateletderived mediators and asked whether platelets contain MIF mRNA. Moreover, we probed the functional role of platelet-derived MIF in inflammatory cell recruitment. Using Western blot and ELISA, we demonstrated and quantitated MIF protein in human and mouse platelets. Applying confocal-microscopy, MIF was found to localise in granularlike structures, but did not co-localise with known platelet cytokines. qPCR indicated that platelets contain low levels of MIF mRNA. ELISA measurements from human platelet supernatants showed that, whereas thrombin and collagen triggered the release of MIF and CXCL12, ADP and oxidised LDL promoted CXCL12 but not MIF secretion. Using Transwell assays, we demonstrated that platelet supernatants promoted monocyte chemotaxis and that this was blocked by neutralising MIF antibodies. This is the first report demonstrating MIF secretion from activated platelets, suggesting that platelets are a previously unrecognised source of MIF in inflammatory processes. There are distinct activating stimuli for MIF and CXCL12 secretion. A substantial portion of the chemotactic capacity of stimulated platelet supernatants is contributed by MIF, suggesting a role for platelet-derived MIF in atherogenic cell recruitment.

Keywords

Atherosclerosis - chemokines - cytokines - inflammatory mediators - macrophage

Full Text

References

References
1 Gawaz M, Neumann FJ, Dickfeld T. et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 1998; 98: 1164-1171.
2 Gawaz M, Brand K, Dickfeld T. et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 2000; 148: 75-85.
3 Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis. Hematology Am Soc Hematol Educ Program 2011; 2011: 51-61.
4 Furman MI, Benoit SE, Barnard MR. et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31: 352-358.
5 Garcia A, Prabhakar S, Brock CJ. et al. Extensive analysis of the human platelet proteome by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2004; 4: 656-668.
6 Baltus T, von Hundelshausen P, Mause SF. et al. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J Leukoc Biol 2005; 78: 435-441.
7 Diacovo TG, Puri KD, Warnock RA. et al. Platelet-mediated lymphocyte delivery to high endothelial venules. Science 1996; 273: 252-255.
8 Maugeri N, Evangelista V, Celardo A. et al. Polymorphonuclear leukocyte-platelet interaction: role of P-selectin in thromboxane B2 and leukotriene C4 cooperative synthesis. Thromb Haemost 1994; 72: 450-456.
9 Nagata K, Tsuji T, Todoroki N. et al. Activated platelets induce superoxide anion release by monocytes and neutrophils through P-selectin (CD62). J Immunol 1993; 151: 3267-3273.
10 Jensen MK, de Nully Brown P, Lund BV. et al. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 2001; 66: 143-151.
11 Dickfeld T, Lengyel E, May AE. et al. Transient interaction of activated platelets with endothelial cells induces expression of monocyte-chemoattractant protein-1 via a p38 mitogen-activated protein kinase mediated pathway. Implications for atherogenesis. Cardiovasc Res 2001; 49: 189-199.
12 Schomig A, Gawaz M, Neumann FJ. et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 1998; 98: 1164-1164.
13 Coppinger JA, Cagney G, Toomey S. et al. Characterisation of the proteins released from activated platelets leads to localisation of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103: 2096-2104.
14 Massberg S, Konrad I, Schurzinger K. et al. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med 2006; 203: 1221-1233.
15 Wurster T, Stellos K, Haap M. et al. Platelet expression of stromal-cell-derived factor-1 (SDF-1): An indicator for ACS? Int J Cardiol. 2011
16 Zernecke A, Bernhagen J, Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation 2008; 117: 1594-1602.
17 Morand EF, Leech M, Bernhagen J. MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 2006; 5: 399-410.
18 Bernhagen J, Krohn R, Lue H. et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007; 13: 587-596.
19 Weber C, Kraemer S, Drechsler M. et al. Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc Natl Acad Sci USA 2008; 105: 16278-16283.
20 Schwartz V, Lue H, Kraemer S. et al. A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett 2009; 583: 2749-2757.
21 Lue H, Thiele M, Franz J. et al. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 2007; 26: 5046-5059.
22 Lue H, Dewor M, Leng L. et al. Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74. Cell Signal 2011; 23: 135-144.
23 Flaster H, Bernhagen J, Calandra T. et al. The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol 2007; 21: 1267-1280.
24 Burger-Kentischer A, Goebel H, Seiler R. et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 2002; 105: 1561-1566.
25 Calandra T, Bernhagen J, Mitchell RA. et al. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994; 179: 1895-1902.
26 Simons D, Grieb G, Hristov M. et al. Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment. J Cell Mol Med 2011; 15: 668-678.
27 Bernhagen J, Calandra T, Mitchell RA. et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993; 365: 756-759.
28 Lan HY, Bacher M, Yang N. et al. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 1997; 185: 1455-1465.
29 Jacquel A, Herrant M, Defamie V. et al. A survey of the signaling pathways involved in megakaryocytic differentiation of the human K562 leukaemia cell line by molecular and c-DNA array analysis. Oncogene 2006; 25: 781-794.
30 Martiney JA, Sherry B, Metz CN. et al. Macrophage migration inhibitory factor release by macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: possible role in the pathogenesis of malarial anemia. Infect Immun 2000; 68: 2259-2267.
31 Kleemann R, Hausser A, Geiger G. et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 2000; 408: 211-216.
32 Goessler UR, Bugert P, Bieback K. et al. Expression of collagen and fiber-associated proteins in human septal cartilage during in vitro dedifferentiation. Int J Mol Med 2004; 14: 1015-1022.
33 Zimmerman GA, Weyrich AS. Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. Arterioscl Thromb Vasc Biol 2008; 28: s17-24-s17-24.
34 van Nispen tot Pannerden H, de Haas F, Geerts W. et al. The platelet interior revisited: electron tomography reveals tubular alpha-granule subtypes. Blood 116: 1147-1156.
35 Martens L, van Damme P, van Damme J. et al. The human platelet proteome mapped by peptide-centric proteomics: a functional protein profile. Proteomics 2005; 5: 3193-3204.
36 Chatterjee M, Huang Z, Zhang W. et al. Distinct platelet packaging, release, and surface expression of proangiogenic and antiangiogenic factors on different platelet stimuli. Blood 117: 3907-3911.
37 Italiano Jr. JE, Richardson JL, Patel-Hett S. et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: 1227-1233.
38 Kamykowski J, Carlton P, Sehgal S. et al. Quantitative immunofluorescence mapping reveals little functional coclustering of proteins within platelet α-granules. Blood 2011; 118: 1370-1373.
39 Liao B, Zhong B-l, Li Z. et al. Macrophage migration inhibitory factor contributes angiogenesis by up-regulating IL-8 and correlates with poor prognosis of patients with primary nasopharyngeal carcinoma. J Surg Oncol 2010; 102: 844-851.
40 Flieger O, Engling A, Bucala R. et al. Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett 2003; 551: 78-86.
41 Merk M, Baugh J, Zierow S. et al. The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. J Immunol 2009; 182: 6896-6906.
42 Nickel W, Rabouille C. Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol 2009; 10: 148-155.
43 Kieffer N, Guichard J, Farcet JP. et al. Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem 1987; 164: 189-195.
44 Newman PJ, Gorski J, White 2nd GC. et al. Enzymatic amplification of platelet-specific messenger RNA using the polymerase chain reaction. J Clin Invest 1988; 82: 739-743.
45 Bugert P, Dugrillon A, Gunaydin A. et al. Messenger RNA profiling of human platelets by microarray hybridisation. Thromb Haemost 2003; 90: 738-748.
46 Schubert P, Devine DV. De novo protein synthesis in mature platelets: a consideration for transfusion medicine. Vox Sang 2010; 99: 112-122.
47 Stellos K, Sauter R, Fahrleitner M. et al. Binding of oxidized low-density lipoprotein on circulating platelets is increased in patients with acute coronary syndromes and induces platelet adhesion to vascular wall in vivo--brief report. Arterioscler Thromb Vasc Biol 2012; 32: 2017-2020.
48 Stellos K, Bigalke B, Langer H. et al. Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells. Eur Heart J 2009; 30: 584-593.
49 Muller II, Muller KA, Schonleber H. et al. Macrophage migration inhibitory factor is enhanced in acute coronary syndromes and is associated with the inflammatory response. PLoS One 2012; 7: e38376
50 Schwartz V, Kruttgen A, Weis J. et al. Role for CD74 and CXCR4 in clathrin-dependent endocytosis of the cytokine MIF. Eur J Cell Biol 2012; 91: 435-449.
51 Langer H, May AE, Daub K. et al. Adherent platelets recruit and induce differentiation of murine embryonic endothelial progenitor cells to mature endothelial cells in vitro. Circ Res 2006; 98: e2-10.
52 Stellos K, Langer H, Daub K. et al. Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. Circulation 2008; 117: 206-215.
53 Schober A, Bernhagen J, Thiele M. et al. Stabilisation of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 2004; 109: 380-385.
54 Chen Z, Sakuma M, Zago AC. et al. Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 709-714.
55 Bucala R. MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. FASEB J 1996; 10: 1607-1613.
56 Bacher M, Metz CN, Calandra T. et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996; 93: 7849-7854.
57 Huhn D, Rodt H, Thierfelder S. Immunhistochemische Untersuchungen an T-Lymphozyten der Maus. Ann Hematol 1974; 28: 415-429.
58 Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci USA 2006; 103: 4930-4934.

Supplementary Material

Online Supplementary Material (PDF) (PDF) (opens in new window)